Release Time:2019-03-09  Hits:

Indexed by: Journal Article

Date of Publication: 2013-01-01

Journal: EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Included Journals: Scopus、PubMed、SCIE

Volume: 59

Page Number: 141-149

ISSN: 0223-5234

Key Words: Mcl-1; Small molecule inhibitor; Fragment-based approach; Anticancer

Abstract: Based on a known nanomolar Bcl-2 homology domain 3 (BH3) mimetic 3-thiomorpholin-8-oxo-8H-acenaphtho[1,2-b] pyrrole-9-carbonitrile (SI, MW: 331), we applied a fragment-based approach to obtain BH3 mimetics with improved affinity and improved solubility in a water ethanol (9:1) cosolvent. After the deconstruction of 1 (S1), we obtained fragment cyanoacetamide (4), which was determined to be a ligand efficiency (LE) hot part. After a rational optimization through fragment evolution beginning with fragment 4, a smaller Mcl-1 inhibitor (E,E)-2-(benzylaminocarbonyl)-3-styrylacrylonitrile (4g, MW: 288) with a 6-fold increase in affinity compared to I was obtained, as predicted by our optimization curve and identified by Mcl-1 protein nuclear magnetic resonance (NMR). (C) 2012 Elsevier Masson SAS. All rights reserved.